CD274 and triple-negative breast carcinoma: Early phase studies of PD-1 or PD-L1 antibodies in heavily pre-treated triple negative breast cancer (TNBC) patients demonstrated response rates of 18–24% whereas endocrine receptor (ER)–positive breast cancer has shown response rates of 12% in patients with tumors expressing PD-L1 [2–5].